Key result
Baseline LVEDV (P=0.012) and global longitudinal strain (P=0.0065) predicted major adverse cardiac events in anthracycline-treated patients with a pre-chemotherapy LVEF of 50-59%.
Why the study?
Do baseline echocardiographic parameters of LV size and function predict symptomatic heart failure or cardiac death in patients treated with anthracyclines who have a pre-chemotherapy LVEF of 50-59%?
Cohort (n=158)
Do baseline echocardiographic parameters of LV size and function predict symptomatic heart failure or cardiac death in patients treated with anthracyclines who have a pre-chemotherapy LVEF of 50-59%?
p-value: p=0.012 for LVEDV, 0.0065 for GLS
No takes yet. Share an insight, caveat, or question.
May support pre-treatment risk stratification; hypothesis-generating and should not yet change practice.
Mousavi-Niri et al. (2015) conducted a cohort in Patients treated with anthracyclines with a pre-chemotherapy LVEF of 50-59% (n=158). Baseline echocardiographic parameters of left ventricular size and function (LVEDV, GLS) was evaluated on Symptomatic heart failure or cardiac death (major adverse cardiac events, MACE) (p=0.012 for LVEDV, 0.0065 for GLS). Baseline LVEDV (P=0.012) and global longitudinal strain (P=0.0065) predicted major adverse cardiac events in anthracycline-treated patients with a pre-chemotherapy LVEF of 50-59%.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: